Hormone Replacement Therapy Dosing for Male-to-Female Gender-Affirming Care
For male-to-female gender-affirming hormone therapy, start with oral estradiol 2 mg daily (not conjugated estrogens or ethinyl estradiol) combined with spironolactone 100-300 mg daily, targeting estradiol levels of 100-200 pg/mL and testosterone <50 ng/dL, with transdermal estradiol preferred in patients over 40 years or those at higher thromboembolic risk. 1, 2
Estrogen Component
First-Line Estrogen Options
The cornerstone of feminizing therapy is 17β-estradiol (not synthetic estrogens). Available formulations include:
- Oral estradiol: 2-6 mg daily (typical starting dose 2 mg) 1, 2
- Transdermal patches: 50-100 μg daily (changed twice weekly or weekly depending on brand) 1
- Parenteral estradiol valerate or cypionate: Injectable formulations 1
Critical Formulation Considerations
Avoid ethinyl estradiol entirely - it carries a 20-fold increased risk of venous thromboembolism and cannot be monitored by serum levels 1, 3. The Dutch cohort demonstrated this risk decreased substantially after discontinuing ethinyl estradiol 1.
Transdermal estradiol is strongly preferred for patients ≥40 years old due to lower thromboembolism risk by avoiding first-pass hepatic metabolism 1, 2. While oral estradiol is safer than conjugated estrogens and allows serum monitoring, transdermal preparations confer additional cardiovascular safety 1, 2.
Injectable Estrogen Dosing - Important Update
Recent evidence suggests current guidelines overestimate injectable estradiol doses. The 2009 Endocrine Society guidelines recommend 2-10 mg weekly, but newer data shows:
- 3-4 mg estradiol valerate weekly achieves physiologic levels in most patients 4
- 78% of patients on 3 mg weekly and 76% on 4 mg weekly achieved estradiol 100-357 pg/mL 4
- Higher guideline-recommended doses (5-10 mg weekly) frequently produce supratherapeutic levels - 91% of patients on mean 5.8 mg weekly had levels above 200 pg/mL 5
Start injectable estradiol at 5 mg weekly or lower to avoid supraphysiologic levels 6. The traditional guideline range of 5-30 mg every 2 weeks or 2-10 mg weekly appears too high based on contemporary data 4, 6, 5.
Antiandrogen Component
Testosterone Suppression Options
Estrogen alone often inadequately suppresses testosterone, requiring adjunctive antiandrogen therapy 1:
Spironolactone 100-300 mg daily - Most commonly prescribed in the United States due to lower cost 1, 2. It directly inhibits testosterone secretion and blocks androgen receptors 1.
Cyproterone acetate - Widely used in Europe as a progestational compound with antiandrogenic properties 1. However, concerns exist about health risks including meningioma risk with prolonged use 7.
GnRH agonists (e.g., goserelin acetate monthly) - Effective with low adverse reaction incidence in a series of 60 patients 1. More expensive but highly effective.
Avoid flutamide - blocks androgen receptors but doesn't lower testosterone and has hepatotoxicity 1.
Target Hormone Levels
Estradiol: 100-200 pg/mL (premenopausal female range) 1, 2
Testosterone: <50 ng/dL (female range) 1, 2
Important Caveat on Target Ranges
Recent systematic review found no evidence that the 100-200 pg/mL range optimizes feminization or reduces adverse events 8. Many patients achieve adequate feminization outside this range. However, sustained supraphysiologic testosterone levels increase adverse reaction risk 1.
Monitoring Protocol
First year: Check estradiol and testosterone every 3 months 2
After first year: Monitor 1-2 times yearly 2
Also monitor: Electrolytes (especially with spironolactone), prolactin, lipids, liver function 1, 2
Dose Adjustment Algorithm
If testosterone remains >50 ng/dL after 3 months:
- Increase spironolactone dose first (up to 300 mg daily) 2
- If inadequate, increase estradiol dose 2
- Consider switching to or adding GnRH agonist 1
If estradiol <100 pg/mL:
Formulation-Specific Dosing Issues
Oral estradiol (mean 2.8 mg daily): 32% of patients had subtherapeutic levels, 14% supratherapeutic 5
Transdermal estradiol (mean 0.09 mg/day): 70% of patients had subtherapeutic levels with guideline-concordant dosing 5 - may require higher doses than traditionally recommended
Injectable estradiol: 91% supratherapeutic with mean 5.8 mg weekly 5 - start lower than traditional guidelines suggest
Critical Safety Considerations
Venous thromboembolism is the most serious complication - 20-fold increase reported with ethinyl estradiol 1. Risk factors include:
Avoid synthetic estrogens (especially ethinyl estradiol) - cannot monitor levels and significantly higher VTE risk 1, 2.
Conjugated estrogens carry higher thromboembolism risk than oral estradiol valerate and cannot be monitored by serum levels 2.
Practical Starting Regimen
For patients <40 years without VTE risk factors:
- Oral estradiol 2 mg daily
- Spironolactone 100 mg twice daily (total 200 mg/day)
- Check levels at 3 months, adjust accordingly
For patients ≥40 years or with VTE risk factors:
- Transdermal estradiol 50-100 μg daily patches
- Spironolactone 100 mg twice daily
- Check levels at 3 months, adjust accordingly
For injectable preference:
- Estradiol valerate 3-4 mg weekly (NOT 5-10 mg)
- Spironolactone 100-200 mg daily
- Check mid-cycle levels at 3 months